Basilea reports presentation of new data for fosmanogepix, isavuconazole and ceftobiprole at IDWeek 2026
- Highlights include oral presentations of pediatric data from the fosmanogepix Expanded Access Program and the activity of its active moiety, manogepix, against Candida auris isolates
Allschwil, Switzerland, October 20, 2026
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that new data on the phase 3 antifungal fosmanogepix, the antifungal isavuconazole (Cresemba®) and the antibiotic ceftobiprole (Zevtera®) will be presented at IDWeek 2026, which takes place from October 21 to 24 in Washington D.C., USA.
Dr. Marc Engelhardt, Chief Medical Officer of Basilea, said: “The breadth of data being presented at IDWeek across Basilea’s anti-infectives portfolio by us, our partners, collaborators and independent research groups, underscores the strong scientific interest in advancing the treatment of serious fungal and bacterial infections. These presentations continue to strengthen the evidence supporting our programs and their potential to address important unmet medical needs, including for pediatric patients.”
| Fosmanogepix data presented at IDWeek 2026 | |
| - | Presentation: Fosmanogepix Expanded Access Experience in Pediatric Patients ≤11 Years of Age with Invasive Mold Infections Presenting author: L. E. Hastings Co-authors: K. L. Barros, M. L. Kussin, M. A. Kutny, J. B. Wood, Y. Vipulanandan, R. Banerjee, D. Dulek, T. S. Sharma, E. Kang, S. Maxwell, A. M. Green, D. Tyungu, M. M. Oldham, J. G. Lake, G. R. Alvira-Arill, E. Kitt, P. Gavin, N. DV De León, Y. Mozo del Castillo, E. Iosifidis, E. Roilides, D. S. Kohlfürst, J. Prattes, M. Hoenigl, O. O’Connor, J. Ryan, A. Howard-Jones, N. Maissen, V. A. Cruz Flores, H. Schlamm, K. Litherland, D. Ionescu, M. Engelhardt, E. Steletou, L. M. Kirkpatrick, J. C. Christenson, P. G. Pappas Date & time: Friday, October 23, 2026, 10:42-10:54 am Location: 201 |
| - | Presentation: Activity of manogepix against Candida auris isolates from the United States Presenting author: M. Winkler Co-authors: A. Klauer, S. Edeker, P. Rhomberg, M. Karr, H. Kimbrough, M. Castanheira Date & time: Friday, October 23, 2026, 4:15-4:30 pm Location: 103 AB |
| - | Poster #P-17: Activity of manogepix against Aspergillus spp. isolates with CYP51 alterations Presenting author: M. Winkler Co-authors: S. Edeker, A. Klauer, P. Rhomberg, M. Karr, H. Kimbrough, M. Castanheira Date & time: Thursday, October 22, 2026, 12:15-1:30 pm Location: Poster Hall B-C |
| - | Poster #P-18: Activity of manogepix against mold isolates across geographic regions Presenting author: M. Winkler Co-authors: S. Edeker, A. Klauer, P. Rhomberg, M. Castanheira Date & time: Thursday, October 22, 2026, 12:15-1:30 pm Location: Poster Hall B-C |
| - | Poster #P-19: Activity of manogepix against yeast and mold isolates from 2025 in the United States Presenting author: M. Winkler Co-authors: S. Edeker, A. Klauer, P. Rhomberg, M. Castanheira Date & time: Thursday, October 22, 2026, 12:15-1:30 pm Location: Poster Hall B-C |
| Isavuconazole data presented at IDWeek 2026 | |
| - | Rapid-Fire Poster Session: Isavuconazole versus Alternative Azoles for Invasive Aspergillus in Solid Organ Transplant Recipients [see also Poster #P-2022] Rapid Fire presenters: M. A. Colaluca, K. Marsh, Y. Li, C. Otto, M. Ringer Date & time: Friday, October 23, 2026, 12:30-12:35 pm Location: RF Arena 1 |
| - | Poster #P-31: Hepatotoxicity Signals Across Azole Antifungals: Is Isavuconazole Safer? A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Presenting author: V. Thiruvadi Co-authors: R. Ravichandran, Y. Kagzi, S. Ahsan, M. Alqaisieh, M. Kandula, D. Francisco Date & time: Thursday, October 22, 2026, 12:15-1:30 pm Location: Virtual Presentation |
| - | Poster #P-1645: Adoption of Isavuconazole in Pediatrics: A Multi-Center Survey Presenting author: C. Lan Co-authors: H. A. Jamal, M. Johnson, S. Vora Date & time: Thursday, October 22, 2026, 12:15-1:30 pm Location: Poster Hall B-C |
| - | Poster #P-1922: Evaluation of Inpatient Isavuconazole Prescribing Practices at a Community-Based Cancer Center Presenting author: W. Monier Texidor Co-authors: S. Kim, J. Unzaga, A. Ramos Morales, L. Kemp, L. Amaya Date & time: Friday, October 23, 2026, 12:15-1:30 pm Location: Poster Hall B-C |
| - | Poster #P-2005: Invasive aspergillosis in kidney transplant recipients: A 20-year cohort from Colombia Presenting author: I. Ramirez Co-author: C. Ruiz Date & time: Friday, October 23, 2026, 12:15-1:30 pm Location: Virtual presentation |
| - | Poster #P-2018: Epidemiology of Invasive Fungal Disease in Allogeneic Hematopoietic Cell Transplant Recipients at a Brazilian Cancer Center (2012–2022): Preliminary Data Presenting author: M. V. Batista Co-authors: A. Volpe, E. Veras; T. Monteiro-Silva, A. Luiza Marinho, B. Cal, A. Cordeiro, V. Bovolenta, M. Nascimento, J. Schmidt-Filho Date & time: Friday, October 23, 2026, 12:15-1:30 pm Location: Poster Hall B-C |
| - | Poster #P-2022: Isavuconazole versus Alternative Azoles for Invasive Aspergillus in Solid Organ Transplant Recipients Presenting author: M. A. Colaluca Co-authors: K. Marsh, Y. Li, C. Otto, M. Ringer Date & time: Friday, October 23, 2026, 12:15-1:30 pm Location: Poster Hall B-C |
| - | Poster #P-1372: Nationwide Retrospective Analysis of Isavuconazole Treatment for Histoplasmosis Presenting author: C. A. Gentry Co-authors: J. J. Farha, S. Thind, R. Williams, II Date & time: Saturday, October 24, 2026, 12:15-1:30 pm Location: Poster Hall B-C |
| - | Poster #P-1378: Effectiveness and Safety of Isavuconazole Compared with Posaconazole as Primary Antifungal Prophylaxis in High-risk Neutropenic Patients with Hematologic Malignancies and Allogeneic Hematopoietic Cell Transplantation Presenting author: F. Herrera Co-authors: D. Torres, N. Mañez, R. Jordán, J. Benso, M. Angel Alderete, Sr., N. Garcia Allende, G. A. Mendez, Sr., M. L. Pereya, L. Tula, A. Manzur, H. I. Peretti, El, C. Salgueira, M. Rodríguez Raimondo, F. Indo, S. Garcia Rojas, P. Callelo, M. Gabriel Castro, V. Fernandéz, A. Risso Patron, C. Niveyro, R. Gago, L. A. Luengo Ackermann, J. Afeltra Date & time: Saturday, October 24, 2026, 12:15-1:30 pm Location: Poster Hall B-C |
| Ceftobiprole data presented at IDWeek 2026 | |
| - | Poster #P-36: Pediatric Dose Selection of Ceftobiprole for Staphylococcus aureus Bacteremia, Including Right-Sided Infective Endocarditis Using Model-Based Approaches Presenting author: A. Tanudra Co-authors: C. Lim, K. Rana, C. M. Rubino, D. Lewis, K. B. Larson Date & time: Thursday, October 22, 2026, 12:15-1:30 pm Location: Poster Hall B-C |
| - | Poster #P-142: In vitro Activity of Ceftobiprole and Comparator Agents Against Contemporary US Clinical Isolates Collected in 2025 Following FDA Approval Presenting author: R. E. Mendes Co-authors: M. Winkler, S. H. Moussa, T. Wiktorowicz, H. Sader, M. Castanheira Date & time: Thursday, October 22, 2026, 12:15-1:30 pm Location: Poster Hall B-C |
| - | Poster #P-381: Extrapolation of Adult Efficacy and Safety to Support Pediatric Use of Ceftobiprole for Acute Bacterial Skin and Skin Structure Infections Presenting author: K. B. Larson Co-authors: R. Tummala, N. C. Close, C. M. Rubino, K. Rana, C. Lim, A. Tanudra, S. McLeod, S. Rege, D. Altarac, D. Lewis Date & time: Saturday, October 24, 2026, 12:15-1:30 pm Location: Poster Hall B-C |
For further information please visit www.idweek.org.
The fosmanogepix development program is funded in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration of Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under OT number: 75A50124C00033. The agreement and federal funding are not an endorsement of study results, product, or company.
For Cresemba® (isavuconazonium sulfate)1 full U.S. prescribing information, please visit: https://www.astellas.us/docs/cresemba.pdf
For ZEVTERA® (ceftobiprole medocaril sodium)2 full U.S. prescribing information, please visit: https://www.zevtera.com/pi
Basilea’s ceftobiprole phase 3 program was funded in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under contract number HHSO100201600002C. The contract and federal funding are not an endorsement of the study results, product, or company. Basilea was awarded approximately USD 111 million, or approximately 75 percent of the costs related to the Staphylococcus aureus bacteremia (SAB) and acute bacterial skin and skin structure infections (ABSSSI) phase 3 studies, regulatory activities and non-clinical work.
About Basilea
Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact:
| Peer Nils Schröder, PhD Head of Corporate Communications & Investor Relations Basilea Pharmaceutica International Ltd, Allschwil Hegenheimermattweg 167b 4123 Allschwil Switzerland | |
| Phone | +41 61 606 1102 |
| media_relations@basilea.com investor_relations@basilea.com |
|
This press release can be downloaded from www.basilea.com.
References
- Astellas Pharma Inc. is the organization responsible for commercializing Cresemba in the U.S.
- Innoviva Specialty Therapeutics is the organization responsible for commercializing Zevtera in the U.S.
Attachment
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
